# DESCRIPTION

## BACKGROUND

- introduce C. trachomatis
- describe STI statistics
- discuss limitations of antibiotic administration
- highlight importance of vaccine development
- describe role of CD4+ T-cells in infection resolution
- discuss Th1 cell-mediated response
- describe antibody responses
- discuss MOMP as a candidate antigen
- highlight need for a nasal mucosae-administered vaccine

## SUMMARY

- summarize methods for treating/preventing Chlamydial infection
- summarize pharmaceutical compositions and immunization methods

## DETAILED DESCRIPTION

- introduce Chlamydia vaccines
- describe vault structure
- detail vault composition
- explain poly ADP-ribosylation reaction
- provide embodiment of vault-like particle
- describe use of vault-like particle as carrier molecule
- introduce vaccine compositions
- describe immunogenic peptides
- detail MOMP fragments
- explain homologous proteins
- describe vaccine administration
- explain cell-mediated immune response
- explain antibody immune response
- define subject
- theorize immunogenicity enhancement
- describe vault-like particle internalization
- explain induction of cell-mediated immune response
- describe protective immunity
- explain reduction of inflammation
- describe nasal immunization
- provide method of using vaults as carriers
- provide method of delivering substances
- describe targeting moiety
- explain Fc binding domain
- provide method of treating or preventing infection
- provide method of treating or preventing disease
- provide method of immunizing against infection
- provide method of reducing infertility
- provide method of eliciting immune response
- provide method of preventing damage
- describe modification of vault-like particles
- describe administration with additional agents
- provide kits for immunizing or treating subjects
- define MVP, VPARP, TEP1, and vRNA
- define vault and vault-like particle
- define MVP, VPARP, TEP1, and vRNA
- describe modifications to MVP, VPARP, and TEP1
- define human and organism
- define environmental medium
- define administering
- describe dosage of vaults or vault-like particles
- define MS2
- define comprise
- describe method of using naturally occurring vaults
- provide vaults
- incorporate substance into vaults
- purify vaults
- administer vaults
- describe vault-like particle
- describe MVP, VPARP, and TEP1 sequences
- describe modifications to MVP, VPARP, and TEP1
- describe adding amino acid sequence to N-terminal of MVP
- describe adding immunogenic peptide to MVP
- describe adding heavy metal binding domain to MVP
- describe adding polynucleotide-binding domain to MVP
- describe adding non-specific polynucleotide-binding peptide to MVP
- describe adding specific DNA binding peptide to MVP
- describe adding specific RNA binding peptide to MVP
- describe adding sensor to MVP
- describe fluorescent protein sensor
- describe modifications to Rattus norvegicus MVP
- describe modifications to human MVP
- describe modifications to Rattus norvegicus TEP1
- describe modifications to human TEP1
- describe modifications to vRNA
- describe vault-like particles
- modify MVP with VPARP or portion of VPARP
- add peptide to C-terminal or N-terminal of VPARP
- create substance-binding domains or sensors
- modify VPARP with CP, GAL4, GL, or MS2
- encode cDNA for modified VPARP
- modify VPARP with LUC
- encode cDNA for modified VPARP with LUC
- modify MVP with immunogenic peptides
- modify MVP with receptor-binding domains
- add amino acid sequence to C-terminal of MVP
- create eukaryotic cell receptor-binding domains
- modify MVP with ANT, TAT, or EGF
- encode cDNA for modified MVP
- modify MVP with anti-CEA scFv diabody
- encode cDNA for modified MVP with anti-CEA scFv diabody
- modify MVP with EGF
- encode cDNA for modified MVP with EGF
- modify MVP with GAL4 and ANT
- encode cDNA for modified MVP with GAL4 and ANT
- modify MVP with GAL4 and αCEA
- encode cDNA for modified MVP with GAL4 and αCEA
- modify MVP with GAL4 and EGF
- encode cDNA for modified MVP with GAL4 and EGF
- modify MVP with GAL4 and TAT
- encode cDNA for modified MVP with GAL4 and TAT
- modify MVP with MS2 and ANT
- encode cDNA for modified MVP with MS2 and ANT
- modify MVP with MS2 and αCEA
- encode cDNA for modified MVP with MS2 and αCEA
- modify MVP with MS2 and EGF
- encode cDNA for modified MVP with MS2 and EGF
- describe vault-like particle embodiments
- define polylysine-MVP-EGF
- define polylysine-MVP-TAT
- describe MVP and VPARP modifications
- describe method of preventing damage
- describe sequestering substances
- describe administering vault-like particles
- describe expressing vault-like particles
- describe detoxifying soil
- describe arsenate reductase enzyme
- describe delivering substances
- describe modified MVP and VPARP
- describe delivering sensors
- describe detecting signals
- describe making vault-like particles
- describe creating polynucleotide sequences
- describe generating bacmid DNA
- describe infecting insect cells
- describe producing vault-like particles
- describe making vault-like particles with substances
- describe purifying and loading vault-like particles

## EXAMPLES

### Example 1

- prepare chlamydia-vault-like particles (CVLPs)
- express MOMP-INT construct in sf9 insect cells
- express rat MVP in sf9 insect cells
- purify vault-like particles
- incorporate MOMP-INT into vaults
- analyze CVLPs by Western blot
- describe MOMP-INT incorporation mechanism
- discuss immunogenic properties of MOMP
- discuss FcR-mediated delivery and Th1 response

### Example 2

- immunize mice with CVLPs
- describe immunization protocol
- analyze bacterial burden following genital infection
- discuss protective immunity induced by CVLPs
- analyze IFNγ+IL-4−CD4+CD3+ cells
- discuss Th1 response and protection
- analyze anti-MoPn antibody response
- discuss IgGc:IgG1 ratio and protection
- analyze Th2 response
- discuss IL-17 response
- describe C. muridarum growth and purification
- describe immunization and challenge protocol
- analyze humoral and cellular responses
- describe gel electrophoresis and immunoblotting
- isolate splenocytes
- analyze intracellular cytokine response

### Example 3

- evaluate vault-induced endocytosis
- describe uptake assay protocol
- analyze incorporation of GL-vaults by BMDCs
- discuss internalization of vaults by BMDCs
- describe bone marrow dendritic cell differentiation

### Example 4

- introduce immunization with peptide containing vaults
- measure serum antibody levels in mice
- compare antibody levels between vault immunization and live infection
- analyze antibody specificity using Western blot
- discuss anti-vault antibody development
- test for antibody production against vaults
- describe antibodies and flow cytometry methods
- outline intracellular cytokine staining protocol
- introduce novel vaccine platform for mucosal surfaces
- describe advantages of vault nanoparticles for immunization
- discuss reduction of inflammation and immune-mediated pathology
- analyze MOMP vaults and IgG to MVP
- discuss scope of the invention and incorporated references

